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CObjectives: Published economic evaluations have reported available
treatments for chronic hepatitis C to be cost-effective as part of the
current approach to disease management, but as standards of care
evolve, their approach to modeling should be reconsidered. This study
aimed to review structural frameworks and key model parameters as
reported in current economic evaluations for treatments for chronic
hepatitis C, and model the impact of variability across parameters on
results. Methods: A systematic review of studies published from 2000
to 2011 was performed. Studies were retrieved from five electronic da-
tabases using relevant search strategies. Model structures, disease
progression rates, utilities, and costs were extracted from included
studies, and were qualitatively reviewed and incorporated into a cost-
utility model. Results: Thirty-four studies were appropriate for data
extraction. A common pathway of six disease states was identified. In
some studies the early disease stages and/or the decompensated cir-
rhosis statewere further subdivided. Large variability in values used for O
t
t
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al So
doi:10.1016/j.jval.2011.06.006isease progression rates, utilities, and costs were identified. When
ncorporated into a model, incremental cost-effectiveness ratios
ICERs) varied: in the least favorable scenario, peginterferon plus riba-
irin was dominated by interferon plus ribavirin; and in the most fa-
orable scenario, peginterferon plus ribavirin dominated interferon
lus ribavirin ($8,544 per quality-adjusted life year [QALY]; costs are
iven in 2008 US dollar amounts). Using mean values the ICER was
15,198 per QALY. Conclusions: Currentmodels use a simplistic struc-
ure resulting from the lack of available data reflecting patient hetero-
eneity. Key model parameters are currently based on a small number
f studies and the variability across these values can affect the inter-
retation of results.
eywords: decision making, economic evaluation, health economics
ethods, hepatitis c, modeling.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Chronic hepatitis C is a major cause of progressive liver disease and
represents a significant and increasing burden in terms ofmorbidity,
mortality, andcosts inbothdevelopedanddevelopingcountries [1,2].
actors such as prevalence, cumulative time of exposure to the hep-
titis C virus (HCV), and genetic and environmental aspects mean
hat the disease burden differs across geographic regions. For exam-
le, the average time elapsed since exposure in Japan, Italy, and
pain means that a high proportion of patients have already pro-
ressed to chronic hepatitis, cirrhosis and, occasionally, hepatocel-
ular carcinoma (HCC); while in theUS, the prevalence of the compli-
ations of disease progression associatedwithHCV, such asHCC, are
redicted to increase over the next 20 to 30 years as the average time
ince exposure increases [3].
Chronic hepatitis C is unique among chronic viral infections in
hat it is considered to be curable, and thus effective treatment, in
erms of sustained virological response (SVR), has substantial
ong-term benefits. Inmany countries, combination antiviral ther-
py with peginterferon alfa plus ribavirin has become the stan-
ard of care [4,5] and is considered cost-effective over a patient’s
ifetime for patients with chronic hepatitis C achieving SVRs of
0% in thosewith genotype 1HCV, and 75% in thosewith genotype
and 3 [6]. A recent review of cost-effectiveness analyses reported
* Address correspondence to: Rebecca Townsend, Cardiff Research C
E-mail: rebecca.townsend@capita.co.uk.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.hat the majority of published incremental cost-effectiveness ra-
ios (ICERs) fall within published acceptability thresholds [7].
The approach to disease management and treatment contin-
ues to evolve, as means of addressing the current and substantial
unmet medical needs in hepatitis C are sought. Indeed, the intro-
duction of the first direct-acting antiviral (DAA) therapy is antici-
pated in 2011. Also, research now indicates that certain biomark-
ers and differential responses to treatment at earlier periods of
measurement (e.g., rapid viral response at 4 weeks) may also in-
fluence long-term treatment success across this heterogeneous
patient group [8–12]. As treatment benefits are maximized in
thosewho respond, and exposure to adverse events and treatment
costs are minimized in those who do not respond, so it can be
expected that cost-effectiveness will be maintained or improved.
To assess the true value of current and future standards of
care, the relevant benefits and costs must be considered over the
lifetime of the patient using appropriate modeling techniques. To
ensure that models are fit-for-purpose and that their interpreta-
tion by payers and society is accurate and appropriate, it is essen-
tial that the design, methodological assumptions, and data input
parameters are relevant to the research question posed. To date, no
one has reviewed the current model frameworks or underlying data
used by published economic evaluations to assess the variability
across analyses or quantify its affect on results. In anticipation of the
rtium, Eastgate House, 35-43 Newport Road, Cardiff CF24 0AB, UK.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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1069V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 6 8 – 1 0 7 7advent of new approaches to treatment and new agents, it is timely
to review the currently available analyses and describe their under-
lying data sources to aid future modeling activities.
The objective of this study is to review the model structural
frameworks and key parameters reported in published economic
evaluations of treatments for chronic hepatitis C, and to use one
such model to explore the impact of variability in key parameters
on resulting ICERs.
Methods
Literature Review
Structured searches of Medline, Medline (R) In-Process, Embase,
Embase In-Process, the Cochrane Library, Health Economic Evalu-
ation Database (HEED), and the National Health Service Economic
Evaluation Database (NHS EED) were conducted between 2000 and
2009. All searches were conducted between June 29 and July 3,
2009, except for HEED, which was searched on August 17, 2009.
The searcheswere re-run onMay 3, 2011 to identify any additional
relevant studies. The search strategy was designed to capture all
relevant articles, and included both free text terms and MeSH
headings (or equivalent for use in Embase) relating to hepatitis C
and economic evaluations. Key terms included: hepatitis C, costs
and cost analysis, economics, and quality-adjusted life years (see
Appendix Table 1 in the Supplemental Materials available at doi:
0.1016/j.jval.2011.06.006).
All identified citationswere reviewedagainst the objectives using
process of positive exclusion, first considering just titles and/or
bstracts and subsequently reviewing full text articles. Theappropri-
te inclusion criteria were as follows: 1) study population of adult
atients (aged18 years or described as adult in the studymethods)
ith chronic hepatitis C; 2) primary economic evaluation or system-
tic review of economic evaluations comparing treatments for
hronic hepatitis C (studies assessing cost of illness, burden of dis-
ase, or thecost-effectivenessof screeningprogramswereexcluded);
nd 3) English language and published between 2000 and 2011. Only
tudies described as cost-utility analyses were included in our re-
iew; studies were excluded if they did not incorporate measures of
uality of life (expressed as utilities). For the purposes of making
omparisonsacross studies, those thatdidnotpresentdisaggregated
ata for any of the parameters of interest in a format that could be
xtracted and thus comparedwere excludedprior to data extraction.
ikewise, studies that modeled a patient population coinfected with
IV, or a population recruited specifically because they experienced
ecurrent hepatitis C following transplant, were excluded prior to
ata extraction.
Data regarding the structural framework and key values for
odel parameters were extracted, where available, from those
rticles meeting the inclusion criteria. The data extraction of
odel parameters included: rates of disease progression (transi-
ion rates), values for health-related quality of life (expressed as
tilities), and mean annual costs of care for each health state.
here there were multiple values for one health state reported,
hose values that represented a male patient aged 40 to 45 years
ith genotype 1 HCV were extracted for inclusion in the analysis.
he number of different values identified for each health state for
ach aspect was used to calculate a mean, and was captured
longside the minimum and maximum value. Extracted values
ere qualitatively assessed; meta-analyses and/or statistical
ooling of the extracted data were not undertaken, and were not
eemed necessary to meet the objectives of this study. Study re-
ults and/or ICERs have not been extracted as they have largely
een reviewed elsewhere [7,13] and are not the subject of this
eview. For comparative purposes, all costs were converted and
nflated to 2008 US dollars using purchasing power parities and
xchange rates appropriate to the year of analysis [14].Analytic Decision Model
The impact on ICERs of altering values for key model parame-
ters across the range identified by this review was assessed
using a life-time Markov decision model based on the design
and assumptions from a previously published model [15]. This
model was chosen because of its simplicity of approach (includ-
ing that it was developed in, and could be easily replicated in,
Microsoft Excel [Microsoft Corporation, Redmond, WA]) and the
completeness of reporting in the publication. To ensure consis-
tency with the original model, the results were validated
against those presented in the publication using the same data
input values and assumptions. To illustrate the impact of the
variability in model parameters used by the studies identified
by this review in a quantitative manner, a base case was chosen
that compared a treatment strategy of peginterferon alfa plus
ribavirin with interferon alfa plus ribavirin. As with the pub-
lished model, treatment was for a maximum of 48 weeks, with
those patients not exhibiting an early virological response (EVR)
ceasing treatment at 12 weeks. The base-case analysis included
a cohort of 1000, treatment-naïve, male patients, with an aver-
age age of 45 years, with genotype 1 HCV and without pre-ex-
isting cirrhosis.
Values for key model parameters (rates of disease progres-
sion, utilities, and costs) were altered according to the mean,
minimum, and maximum values identified in this review to
assess the impact on overall results. The following three anal-
yses were conducted: 1) the mean values for each input param-
eter; 2) equivalence to a least favorable scenario for treatment
with peginterferon alfa plus ribavirin, that is, using the mini-
mum values for rates of disease progression and costs associ-
ated with each health state and the maximum values for utility
associated with each health state (except for the utility of the
SVR health state, which used the minimum identified value);
and 3) equivalence to a most favorable scenario for treatment
with peginterferon alfa plus ribavirin, that is, using the maxi-
mum values for rates of disease progression and cost and the
minimum values for utility (except for the utility of the SVR
health state which used the maximum identified value). During
the analysis the efficacy (proportion of patients achieving SVR)
and the drug acquisition costs were kept constant (i.e., the ef-
fectiveness and drug acquisition costs of the comparative treat-
ment strategies were not altered). The values for SVR and drug
costs were taken from the publication of the original model [15].
Only those values for health states included in the published
model were included in this analysis.
Results
Overview
In total, 3237 individual citations were identified by the
searches, resulting in 34 publications of economic evaluations
describing the cost-effectiveness of treatments for chronic hep-
atitis C that were found to meet the inclusion criteria and were
suitable for data extraction (Fig. 1) [15–48]. The updated
searches identified a further 341 individual citations for review,
of which 4 met the inclusion criteria [49–52]. These four have
not been incorporated into the analysis because they do not
contain any additional model parameters to those already iden-
tified, and hence do not affect the results. The basic character-
istics of the included studies are presented in Appendix Table 2
in the Supplemental Materials available at doi:10.1016/j.j-
val.2011.06.006.
Overall, the findings of this review suggest that, despite the
relatively large number of publications in this area,most are based
1070 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 6 8 – 1 0 7 7on a small number of original studies published in the mid to late
1990s.
Model Framework and Disease Pathway
All of the models identified used a Markov model approach, with
or without a decision tree component, and used a core model
structure based on a disease pathway with six basic health states
(Fig. 2). The exact source informing the model structure was not
always clearly reported, but in those where it was clearly stated,
the most commonly cited underlying model was reported by Ben-
Fig. 1 – Flow chart depicting how records were identified fro
data extraction and analysis.nett et al. [53] in 1997.The findings of this review identified two common variations
to this structure. First, some model structures expanded the
chronic hepatitis C health state to reflect varying levels of disease
severity at model entry, either using broad categories such as
“mild” and “moderate” disease or using a scoring system based on
histological status (Fig. 2). Despite the attempts of thesemodels to
subcategorize patients in the early stages of the disease, theway in
which patients in these states were handled was frequently the
same, irrespective of the disease severity. For example, the rate of
disease progression is the same from each health state, irrespec-
tabases, which resulted in 34 publications suitable form dative of disease severity. Secondly, the decompensated cirrhosis
1071V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 6 8 – 1 0 7 7health statemay be subcategorized into three or six further health
states that represent the three commonmanifestations of decom-
pensated cirrhosis – ascites, variceal hemorrhage, and hepatic en-
cephalopathy (Fig. 2). In those model structures that subcatego-
rized decompensated cirrhosis into six health states, patientsmay
enter the initial state on diagnosis and transition to the subse-
quent state at a later time period (most commonly in the second
and subsequent years).
The approach to modeling both the early chronic hepatitis C and
decompensated cirrhosis health states for all included studies, as re-
ported by the authors, is presented in Appendix Table 3 in the Supple-
mental Materials available at doi:10.1016/j.jval.2011.06.006. It should be
noted that datawere not always available for extraction in the primary
publications, andwehavenot reviewedor extracteddata fromsecond-
ary references to populate this table, except where those studies were
identified by our review in their own right.
Disease Progression and Health State Transitions
Across the studies identified, the rates of transition for progres-
Fig. 2 – Example of the Markov model approach, which used
basic health states. Note: all-cause mortality rates are applie
identified by this review. F0, no fibrosis; F1, portal fibrosis w
septa without cirrhosis; F4, cirrhosis. Six core health states:
Decompensated cirrhosis, 4. Hepatocellular carcinoma, 5. Li
core health states: 1. Chronic HCV Infection, 2. Compensated
carcinoma, 5. Liver Transplant (year 1), and 6. Disease specision from one disease state to another were identified as a keydriver of results. For example, slow progression (low transition
rates) has the potential to reduce the benefits of treatment be-
cause fewer patients progress and experience costly events, which
results in increased ICERs, whereas fast progression (high transi-
tion rates) has the potential to overestimate benefit and results in
lower ICERs. It is important that the transition probabilities used
within amodel can be clinically justified for the patient population
and are supported by citable evidence.
Each of the identified studies has incorporated transition rates
from one or more underlying data sources. Data were well re-
ported and easily accessible in most studies; gaps occurred where
certain transitions were not possible. For example, in many stud-
ies it was not possible to progress from the decompensated cirrho-
sis health state to the HCC health state, and in Japanese studies
the transition to transplant was not possible (which is consistent
with local clinical practice in Japan [26]). One study did not report
the disease progression rates following compensated cirrhosis
and referred the reader to two further data sources [24]. The most
commonly cited sources for disease progression rates were nine
re model structure based on a disease pathway with six
nually to all health states in most published models
ut septa; F2, portal fibrosis with rare septa; F3, numerous
hronic HCV Infection, 2. Compensated cirrhosis, 3.
ransplant (year 1), and 6. Disease specific mortality. Six
hosis, 3. Decompensated cirrhosis, 4. Hepatocellular
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published prior to 1997 (range 1989–1997). The single most com-
monly cited source of disease progression was Bennett et al. [53],
having been cited 19 times in studies whose cohort population is
intended to represent the following countries: Belgium [20,21,47],
Germany [40–42], Italy [25], Japan [26,31], Spain [18,34], Sweden
[17,27,35], Switzerland [32], the United Kingdom [22,38], and the
United States [15,48]. Given the small pool of underlying data
sources, it is not surprising that there ismuch overlap between the
data sources for disease progression rates originally cited by Ben-
nett et al. in 1997 and those cited directly by the studies identified
by our review. Indeed 7 of the 11 sources cited by Bennett et al.
overlap with the 9 most common studies cited by the studies in
this review. The use of Bennett et al. illustrates the approach to
choice of input parameters; for example, in some studies all tran-
sitions are referenced to Bennett et al. [53], in others it is specific
Table 1 – Transition probabilities utilized in published cos
Health state
From
Those models with only six core health states
Chronic hepatitis C Compensated
Compensated cirrhosis Decompensate
Hepatocellular
Decompensated cirrhosis Hepatocellular
Transplant (ye
Death
Hepatocellular carcinoma Death
Transplant (year 1) Death
Transplant (year 2) Death
Those models with extended early chronic
hepatitis health states
Mild chronic hepatitis C Moderate chro
Moderate chronic hepatitis C Compensated
No fibrosis Portal fibrosis
Septal fibrosis
Portal fibrosis Septal fibrosis
Septal fibrosis Compensated
F0 F1
Progression through F1, F2, F3, and F4
Those models with extended decompensated
cirrhosis health states
Compensated cirrhosis Ascites
Variceal bleed
Hepatic encep
Ascites Refractory asc
Transplant (ye
Death
Refractory ascites Transplant (ye
Death
Variceal bleeding (year 1) Variceal bleed
Transplant (ye
Death
Variceal bleeding (year 2) Transplant (ye
Death
Hepatic encephalopathy (year 1) Hepatic encep
Transplant (ye
Death
Hepatic encephalopathy (year 2) Transplant (ye
Death
Note that those studies where the authors expanded the early and de
the possible health states, are included in this analysis as having exp
F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis w
maximum; Min, minimum; N/A, not applicable.values, ranging from one transition value [15,22,27,31,40–42] (but pot necessarily the same transition) to eight specific transitions
26]. Although in other studies, the authors do not specify the link
etween values used and underlying sources. There is no pattern
etween how the rates have been used and the specific country
ddressed by the research question.
Transition rates used to represent disease progression through
he six core health states varied considerably (Table 1). There was
uch less variation in transition rates used to represent disease pro-
ression through multiple early stages of chronic hepatitis C and/or
ultiple health states for decompensated cirrhosis, in those
tudies that expanded these health states (Table 1). The greatest
ariation in values used was for the transition from HCC to
eath and the transition from decompensated cirrhosis to
eath, in those studies using a simple model structure with six
asic health states, both of which varied by more than 60%
Table 1). A qualitative review found that there was no apparent
ctiveness analyses identified by this review.
N
Transition probability (%)
Mean Min Max
sis 5 4.6 1.0 7.3
rhosis 5 4.2 1.6 8.5
inoma 7 4.3 1.4 8.3
inoma 6 3.5 0.6 8.3
4 2.3 1.0 3.1
6 28.1 12.9 75.0
11 50.9 19.4 86.0
5 14.5 10.0 21.0
3 5.3 5.0 5.7
epatitis C 4 3.7 2.3 6.0
sis 4 5.1 3.2 7.3
1 5.4 N/A N/A
1 15.4 N/A N/A
1 2.7 N/A N/A
sis 1 5.4 N/A N/A
2 10.4 5.4 15.4
3 9.1 5.4 15.4
2 2.1 1.6 2.5
ear 1) 2 1.4 1.1 1.6
athy (year 1) 2 1.0 0.4 1.6
1 6.7 N/A N/A
3 2.1 1.0 3.1
2 43.0 11.0 75.0
2 2.7 2.2 3.1
1 33.0 N/A N/A
ear 2) 1 56.9 N/A N/A
3 2.1 1.0 3.1
2 57.5 40.0 75.0
2 2.7 2.2 3.1
1 13.0 N/A N/A
athy (year 2) 1 28.9 N/A N/A
3 2.1 1.0 3.1
2 71.5 68.0 75.0
2 2.7 2.2 3.1
1 40.0 N/A N/A
ensated health states, but then employed the same value for each of
d the health state.
re septa; F3, numerous septa without cirrhosis; F4, cirrhosis; Max,t-effe
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1073V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 6 8 – 1 0 7 7gression rates, or the most commonly cited, across the studies
(i.e., none of the studies reported consistently the highest or
lowest rates), and the variation was independent of study het-
erogeneity, such as year of publication or country perspective.
A qualitative review of disease progression rates also identified
that most rates are static – only one probability is assumed for
each transition. This means that the rate at which a patient pro-
gresses through the health states (e.g., from compensated cirrho-
sis to decompensated cirrhosis) is the same despite their age, co-
morbidities, coinfections, genotype, or disease severity at model
entry. In part this is a consequence of having used aMarkov-based
approach to modeling. In the six studies that do present dynamic
transition rates based on age, sex, and/or genotype, this approach
is applied only to the transitions between early (or asymptomatic)
disease and compensated cirrhosis [20,24,25,27,45,48]. After the
patient has complications of hepatitis beyond initial compensated
cirrhosis, the model reverts to a static approach to disease pro-
gression. Few studies attempt to model transition rates based on
disease severity. Furthermore, in many published models, after a
patient achieves SVR they are assumed to suffer no further conse-
quences of their infection [16,18,20,21,23,24,33,34,44,48].
Costs and Health-Related Quality of Life
Costs and health-related quality of life (or utilities) have also been
identified as key drivers of cost-effectiveness. Most data for costs
and utilities were transparent and readily accessible for extrac-
tion. Inmost studies, no cost was reported for the SVR health state
beyond the drug acquisition and sometimes monitoring directly
associated with treatment. Likewise, utilities were missing for the
SVR health state in 16 studies. Although costs and utilities for
most disease complications were well documented for the first
year, there were differences of approach for subsequent years
spent in the same health state, with the common assumption that
each year with a particular complication is associated with the
same costs and utilities as the previous year(s). For example, costs
and utilities for second and subsequent years post-transplant
were not always included, and in those studies that expanded the
decompensated cirrhosis health state, costs and utilities for sec-
ond and subsequent years were not always included.
In the majority of included studies some effort had been made
to identify appropriate local costs for all the health states in-
cluded. Table 2 summarizes the mean, maximum, and minimum
ost utilized for each health state in the models identified. Across
he studies, and after costs were converted to 2008 US dollars, a
arge variation in cost estimates was found for all individual
ealth states, with the least variation associated with the health
tates of early disease. For example, the greatest variation in cost
as associated with the cost of transplantation in the first year.
his variation may largely be due to differences in the manage-
ent of events (e.g., transplantation) between different countries
nd over time. Similar to the assessment of data for progression
ates, a qualitative review of cost data found no apparent pattern
cross the studies with regards to the highest, lowest or most
ommonly used costs. This meant that none of the studies or
roup of studies froma common country perspective, consistently
eported the highest or lowest values for costs; the variability seen
as independent of study heterogeneity. For example, after costs
ere converted to a common currency and year, studies from
ight different country perspectives provided the lowest costs for
t least one health state: Germany [41], Italy [44], Japan [31], Spain
[34], Sweden [35], Taiwan [28], the United Kingdom [22,37,38], and
heUnited States [29,45,48]. Studies from seven different countries
rovided the highest costs for at least one health state: Japan
26,31], Mexico [19], Spain [18], Sweden [17], Switzerland [32], the
United Kingdom [24,36], and the United States [15,29,33,45].
Utilities used to represent the health-related quality of life as-
sociatedwith the six core health states and those representing thehealth states for decompensated cirrhosis, in the studies that ex-
panded these health states, varied considerably; there was much
less variation in utilities used to represent quality of life in the
early stages of chronic hepatitis C (Table 2). The greatest variation
was for the utility of HCC (0.72), whereas the smallest variation in
utilitieswas for the CHC (0.23) health state. Similarly to the assess-
ment of data for progression rates and costs, a qualitative review
across the utilities employed showed no distinguishable pattern
with regards to the highest, lowest or most commonly used val-
ues. For example, there was no particular study that consistently
reported the highest or lowest values and the variability reported
across the studies appeared independent of study differences,
such as year of publication or country perspective.
Closer inspection of the original underlying data sources finds
that many of the sources of utilities do not directly reflect the
country-specific populations that are the subjects of their respec-
tive research questions. For example, of the 34 studies included in
this review, 11 different country perspectives are represented (see
Appendix Table 2 in the Supplemental Materials available at doi:
10.1016/j.jval.2011.06.006), and less than half (15) incorporated
health-related quality of life data from populations directly rele-
vant to their setting, although not all of them exclusively. The
most frequently cited sources of utilities were Wong et al. [62],
Bennett et al. [53], and Siebert et al. [39,63]. Both Wong et al. and
Bennett et al. were published in the late 1990s and used a method
of generating utilities from an expert panel of hepatologists for
direct incorporation into their own cost-effectiveness analyses in
the absence of relevant quality of life data. These studies have
been used to provide utilities for studies from Spain [18,34], Bel-
gium [20], Mexico [19], Sweden [35], Italy [44], the United Kingdom
[22,36,43], and the United States [29,33,45–47]. The utilities of
Siebert et al. [39,63] have been incorporated into studies from Bel-
gium [21], Mexico [19], Sweden [17], Japan [31], Taiwan [28] and
Germany [39–42].
Similar to the rates of disease progression, the utilities used
across all of the studies are static and presented as mean annual
utilities per patient. This means that the utility for each patient in
a particular health state is the same (e.g., the utility of a patient in
the compensated cirrhosis health state is the same despite their
age, comorbidities, coinfections, genotype, or disease severity at
model entry). Again, this is most likely a consequence of having
adopted a Markov-based approach.
Modeling Analysis
The model was used to illustrate the impact of incorporating the
differing values for key model parameters that were identified by
this review. When all values for disease progression, cost, and
utilitywere adjusted to themean of those identified by this review,
the incremental lifetime costs for those treatedwith peginterferon
plus ribavirin were $5,302,976 (2008 US dollars) when compared
with treatmentwith interferonplus ribavirin,whilst the incremental
QALY gain was 349, resulting in an ICER of $15,198 per QALY. In the
least favorable scenario for treatment with peginterferon, the incre-
mental lifetime costs associated with those treated with peginter-
feron plus ribavirin were $803,277 compared with treatment with
interferon plus ribavirin, whereas the incremental QALY loss was
–82. Therefore, the result is that peginterferon plus ribavirin is dom-
inated by interferon plus ribavirin. In themost favorable scenario for
treatment with peginterferon, the incremental lifetime costs associ-
ated with those treated with peginterferon plus ribavirin were
$6,672,072 compared with treatment with interferon plus ribavirin.
In this scenario, the incremental QALY gain was 781, resulting in an
ICERof $8544perQALY,wherebypeginterferonplus ribavirin isdom-
inant over interferon plus ribavirin.
In comparison, the results reported by the original published
model found peginterferon plus ribavirin to be dominant com-
paredwith interferon plus ribavirin in a patient groupweighted by
p
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1074 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 6 8 – 1 0 7 7genotype (1 and 2/3) and, for the same population, results of all
sensitivity analyses were found to be less than $16,500 [15]. For
atients with genotype 1 hepatitis C, the ICER for peginterferon
lus ribavirin was $2600 compared with interferon plus ribavirin.
or patients with genotype 2/3 hepatitis C, treatment with pegin-
erferon plus ribavirin was found to be dominant compared with
nterferon plus ribavirin. In none of the analyses were peginter-
eron plus ribavirin dominated by interferon plus ribavirin [15].
Discussion
The cost-effectiveness of antiviral treatments for chronic hepatitis
C is an area of interest, reflected in the large numbers of studies
identified by this review and those by other reviews [7,13]. A com-
mon framework for modeling chronic hepatitis C has been identi-
fied, which is currently populated with underlying data from a
limited number of sources and associated with a high level of
variability for key model parameters. This variability has the po-
Table 2 – Costs and utilities for each health state in publish
Health state
N Mean
Those models with only six core health states
Chronic hepatitis C 17 462.5
SVR* 4 374.0
Compensated cirrhosis 30 1,550.4
Decompensated cirrhosis 11 13,190.9
Hepatocellular carcinoma 28 19,147.8
Transplant (year 1) 25 107,599.4
Transplant (year 2) 20 16,025.6
Death 2 6,640.6
Those models with extended early chronic
hepatitis health states
Mild 12 188.9
Moderate 12 590.1
F0–F3 1 147.9
Those models with extended decompensated
cirrhosis health states
Ascites 19 5,171.2
Refractory ascites 13 16,092.0
Variceal bleeding (year 1) 19 17,230.0
Variceal bleeding (year 2) 15 6,025.5
Hepatic encephalopathy (year 1) 19 11,160.7
Hepatic encephalopathy (year 2) 12 5,877.5
Note that those studies where the authors expanded the early and de
the possible health states, are included in this analysis as having exp
F0, no fibrosis; F1, portal fibrosis without septa; F2, portal fibrosis wit
minimum; SVR, sustained virological response.
*Costs associated with the SVR are those for managing patients in
treatment.tential to significantly affect resulting ICERs. The findings of thisreview suggest that the data sources on which many economic
evaluations are based may not adequately reflect the patient pop-
ulation or its heterogeneity, and may not be sufficient for the
needs of current and future research questions.
The structure of the studies identified by this reviewwas based
around six core health states, with the two most common devia-
tions being the expansion of the chronic hepatitis C and decom-
pensated cirrhosis health states. This review found that although
some studies have addressed these points by presenting a struc-
ture that expands one ormore of these states. The underlying data
reported for one or more of the model parameters are the same,
thus reducing the value of the perceived expansion. This is despite
the availability of data for each of the possible model parameters
for the expanded states.
The value of the expansion of the early disease states is
through the assessment of the cost-effectiveness of early treat-
ment with antivirals at a time when the response rate is higher,
but the patient may be asymptomatic and many years away from
ost-effectiveness studies identified by this review.
st (2008 US$) Utility
Min Max N Mean Min Max
146.88 1,676.85 8 0.86 0.72 0.95
0.0 731.85 6 0.88 0.71 1.00
321.60 17,486.26 10 0.73 0.55 0.89
2780.94 28,684.45 5 0.60 0.45 0.81
4670.39 43,100.40 10 0.38 0.09 0.81
9661.05 349,246.95 7 0.66 0.45 0.86
2468.81 24,788.40 5 0.75 0.62 0.86
6407.89 6873.42 1 0.00 — —
118.34 260.71 6 0.85 0.73 0.98
118.34 1,738.50 5 0.77 0.66 0.92
147.90 147.90 1 0.79 0.79 0.79
1281.81 20,772.63 9 0.55 0.31 0.81
8228.82 26,399.64 5 0.44 0.2 0.81
3354.95 37,459.67 7 0.47 0.25 0.81
1360.62 29,670.90 3 0.56 0.28 0.81
4705.14 20,772.63 9 0.46 0.2 0.81
1386.12 26,967.15 2 0.56 0.3 0.81
ensated health states, but then employed the same value for each of
d the health state. Costs are given in 2008 US dollars.
e septa; F3, numerous septa without cirrhosis; Max, maximum; Min,
heath state excluding those specifically associated with antiviraled c
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thisdisease states associated with costly complications. However, in
1075V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 6 8 – 1 0 7 7those studies that addressed this issue, the only distinction made
with regards to utilities and costswas between those patients con-
sidered to be experiencing “mild” or “moderate” chronic hepatitis
C, even in those studies that presented a model structure catego-
rized by fibrosis score such as F0, F1, F2, F3, and F4. Progression
rates for patients with early stage disease have been calculated
through a meta-analysis of published prognostic studies [64]. The
value of the expansion of the decompensated cirrhosis health
state is a consequence of the anticipated differences in utility and
cost associated with individual complications of decompensated
disease, and over time (i.e., in the first year or subsequent years). In
some studies in which expanded model structures are presented,
the same values for utility and cost have been used for each of the
possible health states, essentially rendering the visible expansion
of the health statesmeaningless in the analysis. In other cases, the
studies may report different values for one of the aspects of utility
or cost, but not the other (e.g., reporting different costs for those
experiencing ascites or refractory ascites), but reporting the same
utility for both health states. It seems unlikely that if the resources
required to manage refractory ascites are significantly less than
ascites, that the quality of life of those patients experiencing re-
fractory ascites wouldn’t be improved compared with those expe-
riencing ascites.
We have reviewed the underlying data for key model parame-
ters in published cost-effectiveness models, namely disease pro-
gression rates, utilities, and costs. A consistent finding is that
there is a high level of variation in the values used for thesemodel
parameters and, following qualitative review, no apparent pattern
was found regarding how data sources for these parameters have
been chosen or how the variation is distributed across the studies.
For example, for each parameter, one value has not evolved over
time as the most frequently used and it has not been possible to
identify a consensus regarding the use of one value for eachmodel
parameter. With regards to disease progression rates and utilities,
the underlying data can be traced to a small subset of studies
published prior to 1997. In Bennett et al. [53], the authors state that
data on the natural progression of the disease are limited; rates of
disease progression in the study were taken from published stud-
ies, reviewed by a panel of experts, and modified where appropri-
ate. In the discussion, Bennett et al. recognize and describe the
limitations of the data used for rates of progression in their anal-
ysis and state that thesemay need to be adjusted asmore is learnt
about the disease [53]. As a direct result of small number of data
sources onwhich the studies included in our review are based, the
data frequently do not directly reflect the country-specific per-
spective of the research question posed. Because the ICERs
achieved are significantly influenced by these values and in par-
ticular by disease progression rates, their validity is fundamental
to the interpretation of the results.
One common assumption used was that once patients had
achieved SVR, their utility was 1 (10 of the studies), although in
four studies an SVR-specific utility was assigned following treat-
ment success. Patients who enter the SVR state commonly remain
in it for the remainder of the model and, therefore, its associated
costs and utilities have the potential to significantly affect ICERs
and the interpretation of results. The age and comorbidities of a
typical population with hepatitis C render a utility of 1 unlikely,
and may be artificially high, and thus the utility for the SVR state
requires further consideration. For example, a recent analysis
demonstrated that if the utility of the SVR state was age depen-
dent (i.e., utility decreased with increasing patient age), while all
other parameters remained equal, the resulting ICERs would be
higher [65]. Hence misleading and optimistic results may be associ-
atedwith theassumption that thoseachievingSVRhaveautility of 1,
particularly in older patients. It is noteworthy that 20 studies did not
explicitly comment on whether or not the patient may experience
subsequent progression and complications following SVR.Current studies suggest that a number of factors can impact
response to treatment and disease progression, including: age,
gender, aminotransferase (ALT) levels, disease severity, genotype,
comorbidities and coinfections (e.g., HIV), drug use, alcohol abuse,
prior treatment and response to that treatment, and disease pro-
gression [7,66]. All of the models identified by this review adopted
a simple Markov-based framework, many of which were run with
a single cohort based on patients with average baseline character-
istics, and thus they lack the capacity to adequatelymodel patient
heterogeneity. As with other complex and long-term disease and
as our understanding of the disease evolves and the approach to
treatment becomes more complex, this approach may be consid-
ered over-simplistic. The assumption that mean transition prob-
abilities, utilities, and costs apply to all individuals within a cohort
maymask the contributory effects of some patient sub-groups, for
example, those with favorable ICERs in whom therapy may be
most cost-effective, or those with poorer ICERs in whom therapy
may not be considered cost-effective. For example, a recent anal-
ysis demonstrated that using static or age-independent rates of
disease progression has the potential to provide higher ICERs and
misleading and pessimistic results, particularly in older patients
[67]. Accommodating patient heterogeneity and the dynamic na-
ture of an individual’s progression through the disease may be
required to accurately model the future standards of care and ad-
dress future research questions. Indeed the incorporation of a
more dynamic approach to modeling heterogeneous patient pop-
ulations has already been adopted as standard practice in other
therapy areas such as diabetes [68]. Such modeling approaches
will only beworthwhile if sufficient data exist to populate all of the
required input parameters.
The ICERs obtained from this analysis are for illustrative pur-
poses, solely to demonstrate the potential impact of the variability
in underlying data for key model parameters seen across pub-
lished analyses. We have found that the variability in the values
incorporated has the ability to change the resulting ICERs for new
treatments from dominant to dominated, when all other consid-
erations remain equal. More complex interpretation of these re-
sults is limited by our simplistic approach.We have run themodel
using SVR rates for patients with HCV genotype 1 only, and input
values for disease progression, utility, and cost from all identified
studies (i.e., from heterogeneous patient populations including
both those with genotype 1 and other genotypes). The analysis is
still considered insightful because the variability across the ex-
tracted values for these model parameters was independent of
study country perspective, year of analysis, and cohort character-
istics.
This review was limited in the aspects of published cost-effec-
tiveness analyses that could be considered. Some of the older pub-
lications do not report key information required for this assess-
ment, thus the analysismay be biased towards newer studieswith
more complete reporting. In addition, many small differences are
seen between individual models, and it was beyond the scope of
this study to assess all of these. For example, the possible transi-
tions to and from transplantation varied across the identified
studies, and in some studies transplantation was not included at
all, largely as a consequence of local disease management strate-
gies. Furthermore, it’s possible that differences between studies,
such as country perspective and year, may affect results, and by
using simply the maximum, minimum, and mean we may have
masked these differences.We did not deem it necessary to control
for possible country-specific variation because the underlying
data used for transitions and utilities were rarely directly relevant
to the country perspective, and as a result of a lack of good quality
data, were commonly taken from a small pool of studies and uti-
lized in good faith irrespective of their country of origin. Hence,
conducting the analysis by country would not provide a more
valuable result than those presented from this analysis. For simi-
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1076 V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 6 8 – 1 0 7 7lar reasons, it was not deemed necessary to account for the age of
the study; the underlying data sources are the same for more re-
cent studies as they are for older studies. Other approaches to
weighting the mean were not considered because of inconsisten-
cies in the approach to reporting data and underlying data
sources.
Our review excluded a small number of studies that recruited
patients specifically because of their comorbidities and coinfec-
tions in order to permit comparability across the greatest number
of studies. However, it is likely that in the future, to achieve opti-
mal effectiveness and cost-effectiveness, antiviral treatment will
be tailored to specific patient groups based on their individual
characteristics. The prognostic factors associated with these
groups should be specifically addressed in anymodeling activities
intended to assess the cost-effectiveness of treating such sub-
groups.
As the treatment landscape continues to evolve, we anticipate
that the research questions of the future will address the hetero-
geneity that exists in a normal HCV-infected population, and will
incorporate a new set of early markers of treatment effectiveness,
in addition to rapid viral response that may emerge to help clini-
cians optimize patient outcomes, and mechanisms for screening
to identify those patients most likely to benefit from treatment
before antiviral therapy is initiated [69]. With this in mind, the
future modeling framework will require increased flexibility and
the ability to tailor analyses for individual patients. This may ne-
cessitate a move away from a Markov modeling approach and
introduce the use of discrete event simulation. In addition, greater
emphasis should be placed on justifying the choice of underlying
data and ensuring that data used are the best available that are
relevant to the research question. It is recognized that to obtain
such data may require long-term observational studies or pro-
spective data collection, conducted over possibly decades.
In conclusion, economic evaluations to date have been based
on a common andwell-acceptedmodel framework that is simplis-
tic as a consequence of the lack of available data reflecting patient
heterogeneity. Despite the paucity of data for incorporation into
these studies, there is high variability across the input parameters
used, which can have a significant impact on the results obtained.
For future modeling activities is it important that the model
framework and underlying data sources are appropriate to ad-
dress the research question posed. As our knowledge of hepatitis C
and itsmanagement continues to evolve, further research regarding
improved characterization of chronic hepatitis C, its progression
within the context of the current and future patient populations
and treatment options, and the accuracy of the health-related
quality of life and costs associated with each health state is re-
quired to improve the accuracy of such analyses.
Source of financial support: This study was funded by, and the
writing of thismanuscriptwas supported by, an unrestricted grant
from Bristol-Myers Squibb to Rebecca Townsend and Phil McE-
wan.
Supplementary Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at doi:10.1016/j.jval.2011.06.006,
or, if a hard copy of article, at www.valueinhealthjournal.com/
issues (select volume, issue, and article).
R E F E R E N C E S[1] Lavanchy D. The global burden of hepatitis C. Liver Int 2009;29(Suppl
1):74–81.
[[2] Sweeting MJ, De Angelis D, Brant LJ, et al. The burden of hepatitis C in
England. J Viral Hepat 2007;14:570–76.
[3] Tanaka Y, Hanada K, Mizokami M, et al. A comparison of the
molecular clock of hepatitis C virus in the United States and Japan
predicts that hepatocellular carcinoma incidence in the United States
will increase over the next two decades. Proc Natl Acad Sci USA 2002;
99:1558–89.
[4] National Institute for Health and Clinical Excellence . Peginterferon
alfa and ribavirin for the treatment of mild chronic hepatitis C [NICE
technology appraisal guidance106]. Revised November 2007. Available
from: http://www.nice.org.uk/nicemedia/live/11590/33534/33534.pdf
[Accessed July 5, 2011].
[5] Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for
the Study of Liver Diseases. Diagnosis, management, and treatment of
hepatitis C: an update. Hepatology 2009;49:1335–74.
[6] National Institute for Health and Clinical Excellence. Interferon alfa
(pegylated and non-pegylated) and ribavirin for the treatment of
chronic hepatitis C [technology appraisal 75]. January 2004. Available
from: http://www.nice.org.uk/nicemedia/live/11524/32809/32809.pdf
[Accessed April 12, 2010].
[7] Sroczynski G, Esteban E, Conrads-Frank A, et al. Long-term
effectiveness and cost-effectiveness of antiviral treatment in hepatitis
C. J Viral Hepat 2010;17:34–50.
[8] von Wagner M, Huber M, Berg T, et al. Peginterferon--2a (40KD) and
ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic
hepatitis C. Gastroenterology 2005;129:522–27.
[9] Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV
genotype 1 patients responding to 24 weeks peginterferon -2a (40
kd)/ribavirin therapy. Hepatology 2006;43:954–60.
10] Mangia A, Minerva N, Bacca D, et al. Individualized treatment
duration for hepatitis C genotype 1 patients: a randomized controlled
trial. Hepatology 2008;47:43–50.
11] Tanaka Y, Nishida N, Sugiyama M Tanaka Y, et al. Genome-wide
association of IL28B with response to pegylated interferon- and
ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105–9.
12] Suppiah V, Moldovan M, Ahlenstiel G, et al. IL28B is associated with
response to chronic hepatitis C interferon- and ribavirin therapy. Nat
Genet 2009;41:1100–4.
13] Wong JB. Hepatitis C: cost of illness and considerations for the
economic evaluation of antiviral therapies. Pharmacoeconomics 2006;
24:661–72.
14] Shemilt I, Thomas J, Morciano M. A web-based tool for adjusting costs
to a specific target currency and price year. Evidence and Policy 2010;
6:51–9.
15] Sullivan SD, Jensen DM, Bernstein DE, et al. Cost-effectiveness of
combination peginterferon alpha-2a and ribavirin compared with
interferon alpha-2b and ribavirin in patients with chronic hepatitis C.
Am J Gastroenterol 2004;99:1490–6.
16] Annemans L, Warie H, Nechelput M, Peraux B. A health economic
model to assess the long term effects and cost-effectiveness of PEG
IFN alpha-2a in hepatitis C virus infected patients. Acta Gastroenterol
Belg 2004;67:1–8.
17] Bernfort L, Sennfalt K, Reichard O. Cost-effectiveness of peginterferon
alfa-2b in combination with ribavirin as initial treatment for chronic
hepatitis C in Sweden. Scand J Infect Dis 2006;38:497–505.
18] Buti M, Casado MA, Fosbrook L, et al. Cost-effectiveness of
combination therapy for naive patients with chronic hepatitis C.
J Hepatol 2000;33:651–58.
19] García-Contreras F, Nevárez-Sida A, Constantino-Casas P, et al. Cost-
effectiveness of chronic hepatitis C treatment with thymosin alpha-1.
Arch Med Res 2006;37:663–73.
20] Gerkens S, Nechelput M, Annemans L, et al. A health economic model
to assess the cost-effectiveness of pegylated interferon alpha-2a and
ribavirin in patients with moderate chronic hepatitis C and
persistently normal alanine aminotransferase levels. Acta
Gastroenterol Belg 2007;70:177–87.
21] Gerkens S, Nechelput M, Annemans L, et al. A health economic model
to assess the cost-effectiveness of PEG IFN alpha-2a and ribavirin in
patients with mild chronic hepatitis C. J Viral Hepat 2007;14:523–36.
22] Grieve R, Roberts J. Economic evaluation for hepatitis C. Acta
Gastroenterol Belg 2002;65:104–9.
23] Grieve R, Roberts J, Wright M, et al. Cost effectiveness of interferon
alpha or peginterferon alpha with ribavirin for histologically mild
chronic hepatitis C. Gut 2006;55:1332–38.
24] Grishchenko M, Grieve RD, Sweeting MJ, et al. Cost-effectiveness of
pegylated interferon and ribavirin for patients with chronic hepatitis C
treated in routine clinical practice. Int J Technol Assess Health Care
2009;25:171–80.
25] Hornberger J, Farci P, Prati D, et al. The economics of treating chronic
hepatitis C patients with peginterferon alpha-2a (40 kDa) plus
ribavirin presenting with persistently normal aminotransferase. J Viral
Hepat 2006;13:377–86.26] Ishida H, Inoue Y, Wong JB, Okita K. Cost-effectiveness of ribavirin
plus interferon alpha-2b for either interferon relapsers or non-
[[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
1077V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 6 8 – 1 0 7 7responders in chronic hepatitis C: a Japanese trial. Hepatol Res
2004;28:125–36.
27] Lidgren M, Hollander A, Weiland O, Jonsson B. Productivity
improvements in hepatitis C treatment: impact on efficacy, cost, cost-
effectiveness and quality of life. Scand J Gastroenterol 2007;42:867–77.
28] Lin WA, Tarn YH, Tang SL. Cost-utility analysis of different peg-
interferon alpha-2b plus ribavirin treatment strategies as initial
therapy for naive Chinese patients with chronic hepatitis C. Aliment
Pharmacol Ther 2006;24:1483–93.
29] Marshall D, Simpson K, Martinol M, et al. Economic analysis of early
serum hepatitis C virus RNA testing in patients with chronic hepatitis
C on interferon therapy. J Drug Assess 2000;3:47–62.
30] Nakamura J, Kobayashi K, Toyabe S, et al. The cost-effectiveness of
the new protocol reflecting rapid virologic response to peginterferon
alpha-2b and ribavirin for chronic hepatitis C. Eur J Gastroenterol
Hepatol 2007;19:733–9.
31] Nakamura J, Toyabe SI, Aoyagi Y, Akazaw K. Economic impact of
extended treatment with peginterferon alpha-2a and ribavirin for
slow hepatitis C virologic responders. J Viral Hepat 2008;15:293–99.
32] Sagmeister M, Wong JB, Mullhaupt B, Renner EL. A pragmatic and
cost-effective strategy of a combination therapy of interferon alpha-2b
and ribavirin for the treatment of chronic hepatitis C. Eur J
Gastroenterol Hepatol 2001;13:483–8.
33] Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness
of treatment for chronic hepatitis C infection in an evolving patient
population. JAMA 2003;290:228–37.
34] San Miguel R, Mar J, Cabasés JM, et al. Cost-effectiveness analysis of
therapeutic strategies for patients with chronic hepatitis C previously
not responding to interferon. Aliment Pharmacol Ther 2003;17:765–73.
35] Sennfält K, Reichard O, Hultkrantz R, et al. Cost-effectiveness of
interferon alfa-2b with and without ribavirin as therapy for chronic
hepatitis C in Sweden. Scand J Gastroenterol 2001;36:870–6.
36] Shepherd J, Waugh N, Hewitson P. Combination therapy (interferon
alfa and ribavirin) in the treatment of chronic hepatitis C: a rapid and
systematic review. Health Technol Assess 2000;4:1–67.
37] Shepherd J, Brodin H, Cave C, et al. Pegylated interferon alpha-2a and
-2b in combination with ribavirin in the treatment of chronic hepatitis
C: a systematic review and economic evaluation. Health Technol
Assess 2004;8:iii-iv,1–125.
38] Shepherd J, Jones J, Hartwell D, et al. Interferon alfa (pegylated and
non-pegylated) and ribavirin for the treatment of mild chronic
hepatitis C: a systematic review and economic evaluation. Health
Technol Assess 2007;11:1–224.
39] Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of
peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus
ribavirin for initial treatment of chronic hepatitis C. Gut 2003;52:425–32.
40] Siebert U, Sroczynski G; German Hepatitis C Model GEHMO Group;
HTA Expert Panel on Hepatitis C. Effectiveness and cost-effectiveness
of initial combination therapy with interferon/peginterferon plus
ribavirin in patients with chronic hepatitis C in Germany: a health
technology assessment commissioned by the German Federal
Ministry of Health and Social Security. Int J Technol Assess Health
Care 2005;21:55–65.
41] Siebert U, Sroczynski G, Wasem J, et al. Using competence network
collaboration and decision-analytic modeling to assess the cost-
effectiveness of interferon -2b plus ribavirin as initial treatment of
chronic hepatitis C in Germany. Eur J Health Econom 2005;6:112–23.
[42] Siebert U, Sroczynski G, Aidelsburger P, et al. Clinical effectiveness
and cost effectiveness of tailoring chronic hepatitis C treatment with
peginterferon alpha-2b plus ribavirin to HCV genotype and early viral
response: a decision analysis based on German guidelines.
Pharmacoeconomics 2009;27:341–54.
[43] Stein K, Rosenberg W, Wong J. Cost effectiveness of combination
therapy for hepatitis C: a decision analytic model. Gut 2002;50:253–8.
[44] Sullivan SD, Craxi A, Alberti A, et al. Cost effectiveness of
peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus
ribavirin as initial therapy for treatment-naive chronic hepatitis C.
Pharmacoeconomics 2004;22:257–65.
[45] Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison
population is cost-saving. Hepatology 2008;48:1387–95.
[46] Wong JB, Koff RS. Watchful waiting with periodic liver biopsy versus
immediate empirical therapy for histologically mild chronic hepatitis
C. A cost-effectiveness analysis. Ann Intern Med 2000;133:665–75.[47] Wong JB, Nevens F. Cost-effectiveness of peginterferon alfa-2b plus
ribavirin compared to interferon alfa-2b plus ribavirin as initial
[treatment of chronic hepatitis C in Belgium. Acta Gastroenterol Belg
2002;65:110–11.
48] Yeh WS, Armstrong EP, Skrepnek GH, Malone DC. Peginterferon alfa-
2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus
infection: a cost-utility analysis from the perspective of the Veterans
Affairs Health Care System. Pharmacotherapy 2007;27:813–24.
49] Fonseca MCM, Araújo GTB, Araújo DV. Cost effectiveness of
peginterferon alfa-2B combined with ribavirin for the treatment of
chronic hepatitis C in Brazil Braz J Infect Dis 2009;13:191–9.
50] Gheorghe L, Baculea S. Cost-effectiveness of peginterferon alpha-2a
and peginterferon alpha-2b combination regimens in genotype-1
naive patients with chronic hepatitis C. Hepato-gastroenterology 2010;
101:939–44.
51] Saab S, Hunt DR, Stone MA, et al. Timing of hepatitis C antiviral
therapy in patients with advanced liver disease: a decision analysis
model. Liver Transplantation 2010;16:748–59.
52] Iwasaki Y, Tanaka H, Ikeada H, et al. Efficacy and cost-effectiveness of
consensus interferon monotherapy with high-dose induction for
hepatitis C patients with genotype 2. Scan J Gastroenterol 2011;46:
79–90.
53] Bennett WG, Inoue Y, Beck JR, et al. Estimates of the cost-effectiveness
of a single course of interferon-alpha 2b in patients with histologically
mild chronic hepatitis C. Ann Intern Med 1997;127:855–65.
54] Ascher NL, Lake JR, Emond J, Roberts J. Liver transplantation for
hepatitis C virus-related cirrhosis. Hepatology 1994;20:24S–7S.
55] Christensen E, Krintel JJ, Hansen SM, et al. Prognosis after the first
episode of gastrointestinal bleeding or coma in cirrhosis. Survival and
prognostic factors. Scand J Gastroenterol 1989;24:999–1006.
56] Detre KM, Belle SH, Lombardero M. Liver transplantation for chronic
viral hepatitis. Viral Hepatitis Rev 1996;2:219–28.
57] Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in
compensated cirrhosis type C: a retrospective follow-up study of 384
patients. Gastroenterology 1997;112:464–72.
58] Kilpe VE, Krakauer H, Wren RE. An analysis of liver transplant
experience from 37 transplant centers as reported to Medicare.
Transplantation 1993;56:554–60.
59] Salerno F, Borroni G, Moser P, Badalamenti S, et al. Survival and
prognostic factors of cirrhotic patients with ascites: a study of 134
outpatients. Am J Gastroenterol 1993;88:514–9.
60] Takahashi M, Yamada G, Miyamoto R, et al. Natural course of chronic
hepatitis C. Am J Gastroenterol 1993;88:240–3.
61] Sclerotherapy for male alcoholic cirrhotic patients who have bled
from esophageal varices: results of a randomized, multicenter clinical
trial. The Veterans Affairs Cooperative Variceal Sclerotherapy Group.
Hepatology 1994;20:618–25.
62] Wong JB, Bennett WG, Koff RS, Pauker SG. Pretreatment evaluation of
chronic hepatitis C: risks, benefits, and costs. JAMA 1998;280:2088–93.
63] Siebert U, Ravens-Sieberer U, Greiner W, et al. Patient-based health-
related quality of life in different health stages of chronic hepatitis C
[Abstract]. Hepatology 2001;34:222A.
64] Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific
fibrosis progression rates in chronic hepatitis C virus infection: a
meta-analysis and meta-regression. Hepatology 2008;48:418–31.
65] McEwan P, Yuan Y, Kim R. A need for a dynamic approach to
modeling quality of life weights in cost-effectiveness studies of
antiviral therapies in genotype 1 patients with chronic hepatitis C.
Presented at the International Society for Pharmacoeconomics and
Outcomes Research (ISPOR) Conference; May 16–19, 2010; Atlanta,
Georgia.
66] Freeman AJ, Law MG, Kaldor JM, Dore GJ. Predicting progression to
cirrhosis in chronic hepatitis C virus infection. J Viral Hepat 2003;10:
285–93.
67] McEwan P, Yuan Y, Kim R. The need for a dynamic approach to
modelling disease progression in cost-effectiveness studies on
antiviral therapies in patients with chronic hepatitis C. Presented at
the Asian Pacific Association for the study of the Liver (APASL)
conference; March 25–28, 2010; Beijing, China.
68] Clarke PM, Gray AM, Briggs A, et al. A model to estimate the lifetime
health outcomes of patients with type 2 diabetes: the United Kingdom
Prospective Diabetes Study (UKPDS) outcomes model (UKPDS no. 68).
Diabetologia 2004;47:1747–59.69] Thomas DL, Thio CL, Martin MP, et al. Genetic variation in IL28B and
spontaneous clearance of hepatitis C virus. Nature 2009;461:798–801.
